



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

Molecular Glues

Protein degradation agents based on the ubiquitin-proteasome pathway include a part of molecular glues. Molecular glues are a class of small molecule compounds that can induce or stabilize the interaction between proteins. If one of the protein is ubiquitin ligase, molecular glue can cause another protein to undergo ubiquitin modification and degradation through the proteasome pathway, which is similar to PROTAC. However, these molecules are classified as ligand for E3 ligase as functional molecules in subsequent classification. Older drugs, thalidomide, lenalidomide, and pomalidomide, together with CC-90009 and CC-92480 reported later all belong to this category.


Molecular Glues

(S)-Thalidomide

((S)-(-)-Thalidomide)

Cat. No.: HY-14658A

(S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN).




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eragidomide

(CC-90009)

Cat. No.: HY-130800

Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4^{CRBN} to selectively target GSPT1 for ubiquitination and proteasomal degradation.




Purity: 99.65%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FPFT-2216

Cat. No.: HY-145319

FPFT-2216, a "molecular glue" compound, degrades phosphodiesterase 6D (PDE6D), zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3), and casein kinase 1α (CK1α). FPFT-2216 can be used for the research of cancer and inflammatory disease.




Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HQ461

Cat. No.: HY-144981

HQ461 is a **molecular glue** that promotes CDK12-DDB1 interaction to trigger **cyclin K** degradation. HQ461-mediated degradation of cyclin K impairs CDK12 function, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death.




Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lenalidomide

(CC-5013)

Cat. No.: HY-A0003

Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator.




Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Lenalidomide hemihydrate

(CC-5013 hemihydrate)

Cat. No.: HY-A0003B

Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator.




Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Lenalidomide hydrochloride

(CC-5013 hydrochloride)

Cat. No.: HY-A0003A

Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator.




Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Lenalidomide-d5

(CC-5013-d5)

Cat. No.: HY-A0003S

Lenalidomide-d5 is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mezigidomide

(CC-92480)

Cat. No.: HY-129395

Mezigidomide (CC-92480), a cereblon E3 ubiquitin ligase modulating drug (CELMoD), acts as a molecular glue. Mezigidomide shows high affinity to cereblon, resulting in potent antimyeloma activity.




Purity: 98.02%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

Pomalidomide

(CC-4047)

Cat. No.: HY-10984

Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

<p>Pomalidomide-d3 (CC-4047-d3)</p>	<p>Pomalidomide-d5 (CC-4047-d5)</p>
<p>Pomalidomide-d3 (CC-4047-d3) is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pomalidomide-d5 is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide D4</p>	<p>TMX-4100</p>
<p>Thalidomide D4 is a deuterium labeled Thalidomide. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a K_d of ~250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.</p> <p>Purity: 98.03% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>	<p>TMX-4100 is a selective phosphodiesterase 6D (PDE6D) degrader. TMX-4100 shows a high degradation preference for PDE6D with the DC_{50} values less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4100 can be used for the research of multiple myeloma.</p> <p>Purity: 98.42% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>TMX-4113</p>	<p>TMX-4116</p>
<p>TMX-4113 is a degrader of phosphodiesterase 6D (PDE6D) and casein kinase 1α (CK1α). TMX-4113 can be used for the research of cancer.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TMX-4116 is a casein kinase 1α (CK1α) degrader. TMX-4116 shows the degradation preference for CK1α with DC_{50}s less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4116 can be used for the research of multiple myeloma.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>